Alvotech (NASDAQ: ALVO) and JAMP Pharma Group have jointly announced that Health Canada has granted marketing authorization to JAMP Pharma for AVT04, a biotech analogue of Stelara (ustekinumab) developed by Alvotech. The product will be marketed under the Jamteki brand and manufactured by Alvotech in Reykjavík.

The marketing authorization covers Jamteki in pre-filled syringes, with concentrations of 45 mg/0.5 ml or 90 mg/ml. This marks the second biotech analogue for which the companies have received marketing approval in Canada. Last year, they initiated sales of Simland (AVT02), Alvotech's biotech analogue to Humira (adalimumab).

JAMP Pharma, expressed excitement about expanding their biotech analog offerings and advancing their market strategy with Jamteki. He highlighted the partnership with Alvotech as crucial in improving access to ustekinumab for Canadian patients at a more affordable cost. The JAMP Care service will provide specialist support to aid patients in adapting to the medication.

Alvotech, expressed satisfaction with the marketing authorization for their second biotech drug analog in Canada. He emphasized the strong demand for quality biotech medicines in the Canadian market and the positive impact on healthcare accessibility.

JAMP Pharma aims to lead the biotech analog market in Canada and introduced BIOJAMP in February 2022 to facilitate the adaptation of biotech analogs for patients, doctors, and nurses. The collaboration between Alvotech and JAMP Pharma, initiated in January 2022 and extended in October 2022, covers multiple biotech analogs in various stages of development.

AVT04, a monoclonal antibody and biotech analog to Stelara® (ustekinumab), has received marketing authorization in Canada and Japan. The European Medicines Agency has recommended its marketing authorization in the European Economic Area. Alvotech and JAMP Pharma's collaboration encompasses the launch of Simlandi (adalimumab) and Jamteki (ustekinumab) in Canada, with plans for additional biotech analogs currently in clinical and pre-clinical trials.

 

Source: globenewswire.com

Report Abuse